Palisade Bio Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Palisade Bio Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.86 $ to 2.80 $ · Last price: 1.50 $ (As of: September 28, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/29/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Palisade Bio Inc PALI | 0.3 | 12.7 | 0.6 | 100.0 | -2,339.6 | – | 66.7 |
| Vertex Pharmaceuticals Inc VRTX | 133.5 | 32.0 | 24.4 | 55.0 | 38.1 | 9.6 | 36.8 |
| Moderna Inc MRNA | 78.3 | – | 4.6 | -66.0 | -131.1 | -39.2 | 708.1 |
| Regeneron Pharmaceuticals Inc REGN | 78.2 | 18.9 | 13.5 | 44.5 | 20.7 | 1.0 | 34.1 |
| argenx NV ARGX | 60.5 | 37.2 | 30.7 | 59.1 | 32.0 | 89.6 | 36.6 |
| Revolution Medicines Inc RVMD | 41.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 359.3 |
| BeiGene, Ltd. ONC | 41.5 | 65.5 | 32.4 | 88.9 | 19.1 | 40.2 | 12.6 |
| Alnylam Pharmaceuticals Inc ALNY | 33.9 | 64.3 | 28.6 | 79.7 | 23.0 | 65.2 | -42.8 |
| Royalty Pharma Plc RPRX | 32.2 | 31.5 | 19.2 | 95.8 | 100.3 | 5.1 | 70.0 |
| Median of companies shown | 41.9 | 32.0 | 19.2 | 59.1 | 20.7 | 7.3 | 36.8 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -20 | -21 | -2,525.46 | -16 | 11 | 23 |
| 2017 | 0 | -13 | -16 | -71.34 | -13 | 9 | 14 |
| 2018 | 0 | -8 | -5 | -18.02 | -8 | 6 | 8 |
| 2019 | 0 | -9 | -8 | -35.18 | -7 | 5 | 7 |
| 2020 | 0 | -9 | -10 | -43.48 | -5 | -7 | 3 |
| 2021 | 0 | -42 | -27 | -2,135.60 | -15 | 7 | 13 |
| 2022 | 0 | -16 | -14 | -16.20 | -13 | 12 | 16 |
| 2023 | 0 | -13 | -12 | -26.97 | -11 | 11 | 14 |
| 2024 | 0 | -15 | -14 | -10.20 | -12 | 7 | 11 |
| 2025 | 0 | -18 | -17 | -0.30 | -11 | 129 | 134 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q2 | -3.32 | 58.20 | 0 | – | – | -4 | -4 |
| 2024: Q3 | -2.32 | 68.40 | 0 | – | – | -3 | -3 |
| 2024: Q4 | -0.69 | 89.30 | 0 | 101.60 | -83,600.00 | -2 | -2 |
| 2025: Q1 | -0.47 | 89.80 | 0 | – | – | -2 | -2 |
| 2025: Q2 | -0.58 | 82.50 | 0 | – | – | -2 | -2 |
| 2025: Q3 | -0.38 | 83.60 | 0 | – | – | -4 | -4 |
| 2025: Q4 | -0.06 | 91.90 | 0 | -100.00 | – | -3 | -3 |
| 2026: Q1 | -0.05 | 90.30 | 0 | – | – | -4 | -4 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Risk & Weakness
Value & GARP
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.23 | -0.25 – -0.20 | 0 | 24.8% | 7 |
| 12/31/2027 | -0.28 | -0.40 – -0.20 | 0 | -24.1% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -100.0%
- More than 10% revenue growth is expected for the coming year no data
- Share count grows by less than 3% a year 298.3%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 133 m net cash
- Operating cash flow covers the profits of the last three years 9 m
- Return on capital at 15% or higher, or up versus two years ago -13.9%
- Insiders hold at least 10% or are net buyers 1.6%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -100.0%
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -13.0%
- ROCE > 15% -13.9%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Finley John David | CEO, CFO | Other | 88,400 | 0.00 | – |
The company
About the Company
Palisade Bio, Inc., ein biopharmazeutisches Unternehmen im klinischen Stadium, entwickelt in den Vereinigten Staaten orale Prodrugs von Phosphodiesterase-4-Inhibitoren, die für die gezielte Freisetzung im terminalen Ileum und Kolon konzipiert sind. Zu seinem führenden klinischen Produktkandidaten zählt PALI-2108, das sich in Phase-1b-Studien zur Behandlung von Patienten mit chronisch-entzündlichen Darmerkrankungen, einschließlich Colitis ulcerosa und fibrostenosierendem Morbus Crohn, befindet. Das Unternehmen hat eine Forschungskooperations- und Lizenzvereinbarung mit Giiant Pharma, Inc. zur Entwicklung, Herstellung und Vermarktung seiner Wirkstoffe; eine Lizenzvereinbarung mit den Regents of the University of California ausschließlich zur Aufrechterhaltung der Newsoara-Kooperationsentwicklung; sowie eine Vereinbarung zur gemeinsamen Entwicklung und zum Vertrieb mit Newsoara Biopharma Co., Ltd. Das Unternehmen wurde 2001 gegründet und hat seinen Hauptsitz in Denver, Colorado.
- Employees
- 14
- Headquarters
- Denver, CO
- Address
- 4600 South Syracuse Street, 80237 Denver, United States
- Phone
- 858 704 4900
- Website
- palisadebio.com
- IPO Date
- 12/20/2006
- ISIN
- US6963894026
- Stock Split
- 1:15 on 04/08/2024
- Stock Split
- 1:50 on 11/16/2022
- Stock Split
- 1:6 on 04/28/2021
Management
| Name | Title | Birth Year |
|---|---|---|
| J. D. Finley | CEO, CFO & Director | 1958 |
| Mitchell Lawrence Jones M.D., Ph.D. | President & Chief Medical Officer | 1977 |
| Joerg Heyer Ph.D. | Head of Translational Science & Medicine | – |
| James Izanec M.D. | VP & Head of Clinical Development | – |
| Daniel J. Larkins | Head of Global Regulatory Affairs | – |
| Adarsh Patel M.B.A., M.S. | Head of Chemistry, Manufacturing & Controls | – |
| Dawn Louro | VP & Head of Clinical Operations | – |
| Ryker Willie | Senior VP of Finance & Corporate Controller | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.